Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Number of FDA Drug Approvals Reach a 15-Year High in 2012
Research Driven Investing Provides Stocks Research on ISIS Pharmaceuticals and Keryx

NEW YORK, NY -- (Marketwire) -- 02/01/13 -- A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ Biotechnology Index (IBB), the SPDR S&P Biotech ETF (XBI) and the First Trust Amex Biotechnology Index ETF (FBT) have all gained over 20 percent in the past year, outperforming the broader markets by a good margin. Research Driven Investing examines investing opportunities in the Biotech Industry and provides equity research on ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and Keryx Biopharmaceuticals (NASDAQ: KERX).

Access to the full company reports can be found at:

www.RDInvesting.com/ISIS

www.RDInvesting.com/KERX

Bloomberg recently reported drug approvals by the U.S. Food and Drug Administration reached a 15 year high in 2012. The FDA approved a total of 39 novel medicines last year, an increase of 30 percent when compared to a year ago. Oncology drugs lead the way with 11 new drugs approved last year. Over the last ten years the number of FDA approvals had averaged roughly 23 a year. The passage of the Prescription Drug User Fee Act (PDUFA) played a major role in the sharp increase in approvals.

The PDUFA "has provided critical resources for improving the quality and timeliness of premarket review of drugs," said FDA spokeswoman, Sandy Walsh. "These accomplishments could not have been achieved without the innovations of the biopharmaceutical industry and the dedication and skill of FDA's drug review staff."

Research Driven Investing releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and industry newsletters.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. The company recently reported that the FDA has approved their New Drug Application (NDA) for its cholesterol treatment, Kynamro. The FDA approval triggers a $25 million milestone payment to Isis from its partner Genzyme.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Shares of the company have been on an impressive run since reporting their kidney drug, Zerenex, met primary and all key secondary endpoints in a recent Phase 3 study. The company expects to submit a NDA for Zerenex with the FDA in the second quarter of 2013.

Research Driven Investing has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

http://www.rdinvesting.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
You are a hobbyist; curious student or a developer-entrepreneur then you must get this kit to jump start your IoT development. This is still in Beta but it has everything you need in terms of hardware, software, tools and forums to guide you through. IoT dev kit is a subset of In...
In recurring revenue models, maximizing customer lifetime value (CLV) is achieved through establishing a lifetime of customer interaction points as each provides an opportunity to win revenue and loyalty. While the previous two posts in this CLV miniseries focused on the definition of ...
Hortonworks went through an IPO last Friday, December 12, 2014. It’s initial price of $16 soared by 60% immediately after. Today the stock price is $24.70 with a market cap of $1.02B. Another billion dollar club member. They compete with Cloudera and MapR in packaging the open source H...
When a CIO or a CTO thinks of the applications they support it is almost always in terms of a "portfolio" When a research company named Gleanster poll executives about agile data management they discovered an interesting trend. Companies are reporting an increase in portfolio sizes wi...
The steadily increasing frequency of data breach occurrences in 2014 has been both astounding and worrisome. From Target and Neiman Marcus to Michaels, Chick-fil-A and Home Depot, fraudsters are leaving no stone unturned, and the millions of customers unlucky enough to use infected poi...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE